about
Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsMetabolic regulation of T cell differentiation and functionRegulatory myeloid cells in transplantationAutophagy upregulates (Pro)renin receptor expression via reduction of P62/SQSTM1 and activation of ERK1/2 signaling pathway in podocytes.Sirolimus in pediatric renal transplantation.Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.Immunoregulatory functions of mTOR inhibition.Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Primary care of the renal transplant patient.BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.T cells and lung injury. Impact of rapamycin.Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantationHow tolerogenic dendritic cells induce regulatory T cellsTemsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaquesThe effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.Chemical genomics approach to identify genes associated with sensitivity to rapamycin in the fission yeast Schizosaccharomyces pombe.Use of a small particle solid-core packing for improved efficiency and rapid measurement of sirolimus and everolimus by LC-MS/MS.Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells.A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Tuberous sclerosis complex: neurological, renal and pulmonary manifestationsAntitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.Oral candidiasis in patients with renal transplants.Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated miceReduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.Targeting the Mammalian Target of Rapamycin in Lung Cancer.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.Road to remission: a comprehensive review of therapy in uveitis.An evaluation of sirolimus in renal transplantation.Obesity and metabolic syndrome in kidney transplantation.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.mTOR inhibitors in pediatric kidney transplantation.Phenytoin-induced reduction in sirolimus levels.Tuberous sclerosis complex: the past and the future.The dog aging project: translational geroscience in companion animals.
P2860
Q24187866-BC1A4245-9C17-4F19-916A-AA32C4A4B443Q24201591-7F5B2EC6-E75A-46C7-B239-40776F267DA2Q26798088-6B9B2D58-6900-43F7-918B-F270C423CF43Q26999875-AEE131DB-AC2C-43BF-899E-AAD2B1C32DAAQ30252491-A53CF5BA-1003-4EB1-A7A7-DFBB06C543F3Q33397668-2D460B61-B0CE-45C4-BCF9-A07C8601DD28Q33665207-17489651-6E9F-4C30-AE49-96558FAF3E9AQ33761278-2BF2EE2F-C51F-4CE5-AE84-A042405B5B35Q33848529-C3F328A1-05BE-4447-A2D5-D4E21C6350B7Q33898744-EB19FB96-72D0-490C-B12C-D0B457D4483AQ33934591-F7750D82-61DE-4571-A936-11CC5FE94E77Q34103700-B4AA754E-5C7B-45C9-B2D4-6C5B67F4892EQ34506806-7EB467CE-74B7-4D6C-A51A-86856ED25FDEQ34631825-8767B0ED-53C5-4B24-8B6C-676B2A3F7AF4Q34767073-9DE1B05A-D3E2-44D8-9FE6-DBFB875E5E6BQ34792747-49CCFC77-288B-4682-80B2-725C917BAFCDQ35223564-99FF2275-6363-4D42-819E-E92528EC9C27Q35555201-CAD38981-50ED-4337-A343-E462AF8B1ABFQ35792318-888ABC3F-108D-4CC4-B21E-6BDE9AC994C6Q35964539-DA33E6FB-C9E3-4FD7-880A-90B9E852ACABQ36183858-5ADE8E1B-E107-4451-AE05-35497FB266DBQ36239644-30E8500C-543C-4BA1-B64B-2F032CEE8A19Q36312850-0FEF2378-7AA3-4220-A1C8-F95168C2A116Q36891164-2C6927AF-7769-4B3E-A424-E5D295003311Q36899362-143BE0BF-5835-417E-81B9-625E28BD1F5FQ37068522-7C5BE5C5-D364-456D-B89F-9DC6A97F5A37Q37201250-F8743080-191A-4B79-94C1-12E33AF9C2B3Q37337088-FDC55238-7F5D-4AB2-8CDF-75CAB2BE9DE9Q37615957-6B67F2B9-7F91-4C6D-82A5-54893085C6B2Q37741531-EDC24596-02DD-4397-B9C4-FDAF2BFF05BFQ37760379-BAF2BE37-EB6A-4439-AC9F-FF60EFDEAC84Q37924929-120C0892-D5D3-4F17-8D9F-29928A7C3559Q37936459-09E969F8-60F7-4F3D-BFB9-158DA08B3CCEQ38038696-24619642-C4F2-463F-8C67-1F59900508AEQ38088665-563E436E-624E-4637-B2D8-82AD7B4AAA55Q38094782-163AD6B8-C20B-437B-A2C3-301A264AF1DEQ38112331-06D3FD64-171B-450E-AF01-0FAFF6B4807AQ38261330-E97FE796-EFA1-480B-811D-2BCCCBA0FA2EQ38297624-E2119777-C4CC-4168-9731-14399EA61195Q38824857-3B357635-B059-4F6F-AA53-426AFE914D15
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Use of sirolimus in solid organ transplantation.
@en
type
label
Use of sirolimus in solid organ transplantation.
@en
prefLabel
Use of sirolimus in solid organ transplantation.
@en
P2093
P1433
P1476
Use of sirolimus in solid organ transplantation.
@en
P2093
Donald E Hricik
Joshua J Augustine
Kenneth A Bodziak
P304
P356
10.2165/00003495-200767030-00004
P577
2007-01-01T00:00:00Z
P6179
1044672793